LUMINOUS
(2026)Objective
To evaluate neurofilament light chain (NfL) as a surrogate marker for disease activity in multiple sclerosis by quantifying, across randomized controlled trials, the strength of association between treatment effects on NfL and treatment effects on established clinical and MRI endpoints.
Study Summary
• The analysis quantified the strength of the trial-level association between NfL treatment effects and established outcomes.
• Specific effect estimates, correlation coefficients, and p-values were not reported in the available source text.
Intervention
None — meta-regression of treatment effects from existing randomized controlled trials in multiple sclerosis.
Inclusion Criteria
Randomized controlled trials in multiple sclerosis reporting treatment effects on neurofilament light chain and on clinical and/or MRI disease-activity endpoints.
Study Design
Arms: Not applicable — trial-level meta-regression across multiple randomized controlled trials.
Patients per Arm: Not reported in source
Outcome
• Numerical association strength and significance not provided in the available source text.
Bottom Line
This meta-regression assessed the trial-level relationship between treatment effects on NfL and treatment effects on established clinical and MRI disease-activity endpoints in MS; the magnitude and statistical strength of that association were not reported in the available source text.
Major Points
- Meta-regression of randomized controlled trials in multiple sclerosis evaluating NfL as a surrogate marker for disease activity.
- Quantified the strength of association between treatment effects on NfL and treatment effects on established clinical and MRI endpoints across studies.
- Specific quantitative association estimates and significance values were not available in the source text.
Study Design
- Study Type
- Meta-regression of randomized controlled trials
- Randomization
- No
Primary Outcome
Definition: Strength of the trial-level association between treatment effects on NfL and treatment effects on established clinical and MRI disease-activity endpoints across randomized controlled trials.
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| - |
Citation
Multiple Sclerosis Journal. March 2026. doi:10.1177/13524585251407973. PMID 41574448.